KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

Nat Commun 16(1) 716

PMID39820749
PMCIDPMC11739584
DOI10.1038/s41467-025-56096-2
发表日期2025-01-17
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。
摘要

摘要

Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previous ph1/2 clinical trials. The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2- locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. A total of 275 patients were randomized at 1:1 ratio to receive lerociclib (137 patients, 150 mg twice daily) or placebo (138 patients) plus fulvestrant. Progression-free survival (PFS) assessed by investigators was significantly improved in lerociclib arm versus placebo arm (11.07 vs 5.49 months; hazard ratio, 0.451, 95% CI: 0.311-0.656, P = 0.000016), meeting the pre-specified primary endpoint. The secondary endpoints included PFS assessed by Blinded Independent Central Review (BICR), objective response rate (ORR), duration of response (DOR), disease control rate (DCR), clinical benefit rate (CBR), overall survival (OS), safety and tolerability and pharmacokinetic profile. DOR is not reported, and OS data was immature at the data cut-off but unplanned ad hoc analysis is reported. These findings support lerociclib plus fulvestrant as a treatment option for patients with HR+/HER2- endocrine-resistant advanced breast cancer (ABC). (Funded by Genor Biopharma; LEONARDA-1 ClinicalTrials.gov identifier, NCT05054751.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1CONSORT diagram.
非 KM Figure
Fig. 2Kaplan–Meier analyses of progression-free survival in the intent-to-treat population ( n = 275 patients). A Investigator-assessed and B Blinded Independent Central Review-assessed. HR hazard ratio. The hazard ratio (HR) was derived from a stratified Cox proportional hazards model, and the one-sided p -value was derived from the Log-Rank test. Source data are provided as a Source Data file.
非 KM Figure
Fig. 3Subgroup analysis of progression-free survival (PFS) assessed by Investigator in the intent-to-treat population ( n = 275 patients). HRs are for lerociclib versus placebo. PFS HRs are indicated by diamonds and 95% CIs are indicated by the crossing horizontal lines. Diamond size is proportional to the sample size of each patient subgroup. HRs were estimated based on the unstratified Cox proportional hazards model for the stratification factor related subgroups including menopausal status, visceral metastasis, liver metastasis; stratified Cox proportional hazards model for other subgroups and overall HR. ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, HR hazard ratio, PR progesterone receptor. Source data are provided as a Source Data file.
非 KM Figure